Side effects of statins - Prevalence, relevance, consequences

Wiener Klinische Wochenschrift

Volumn 114, Issue 21-22, 2002, Pages 887-888

  Sinzinger, Helmut ^a  

^a Wilhelm Auerswald Atherosclerosis Research Group   (Austria)

Author keywords

Hepatopathy; Myopathy; Neuropathy; Side effects; Statins

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTILIPEMIC AGENT; CREATINE KINASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; CREATINE KINASE BLOOD LEVEL; DRUG INDUCED DISEASE; DRUG SAFETY; EDITORIAL; ERECTILE DYSFUNCTION; HUMAN; HYPERLIPIDEMIA; LIVER FAILURE; LIVER TOXICITY; MYOPATHY; NONHUMAN; PATHOGENESIS; PERIPHERAL NEUROPATHY; PREVALENCE; RHABDOMYOLYSIS; SYMPTOMATOLOGY;

ALANINE TRANSAMINASE; ANIMALS; ANTICHOLESTEREMIC AGENTS; ANTILIPEMIC AGENTS; CLINICAL TRIALS; COHORT STUDIES; ENZYME TESTS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMPOTENCE; LIVER; LOVASTATIN; MALE; MUSCULAR DISEASES; PERIPHERAL NERVOUS SYSTEM DISEASES; PYRIDINES; RISK ASSESSMENT; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 0037202755     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (17)

1. Rosenson RS, Tangney CC (1998) Antiatherothrombotic properties of statins: Implications for cardiovascular event reduction. JAMA 279: 1643-1650
2. Scandinavian Simvastatin Study Group (1994) Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 344: 1383-1389
3. Staffa JA, Chang J, Green L (2002) Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med 346: 539-540
4. Sinzinger H, Laimer H, Hoppichler F, Toplak H, Kritz H, Kleemann L, Pilz H, Grafinger P, Benzer W, Brainin M, Derfler K, Dzien A, Pidlich J, Pirich C, Lechleitner M, Ludvik B, Mayer G, Silberbauer K, Traindl O (2002) Fünf goldene regeln. Öst Ärztezeitung 22: 38-40
5. Tolman KG (2002) The liver and lovastatin. Am J Cardiol 89: 1374-1380
6. Gaist D, Garcia Rodriguez LA, Huerta C, Hallas J, Sindrup SH (2001) Are users of lipid-lowering drugs at increased risk of peripheral neuropathy? Eur J Clin Pharmacol 56: 931-933
7. Holt S, Reeder, B, Wilson M, Harvey S, Morrow JD, Roberts LJ II, Moore K (1999) Increased lipid peroxidation in patients with rhabdomyolysis. Lancet 353: 358-359
8. Sinzinger H, Wolfram R, Peskar BA (2002) Muscular side effects of statins. J Cardiovasc Pharmacol 40: 163-171
9. Hamilton-Craig I (2001) Statin-associated myopathy. Med J Aust 175: 486-489
10. Gaist D, Garcia Rodriguez LA, Huerta C, Hallas J, Sindrup SH (2001) Lipid lowering drugs and risk of myopathy: A population-based follow-up study. Epidemiology 12: 565-569
11. Evans M, Rees A (2002) Effects of HMG-CoA reductase inhibitors on skeletal muscle: Are all statins the same? Drug Saf 25: 649-663
12. Sinzinger H (1999) Two different types of exercise-induced muscle pain without myopathy and CK-elevation during HMG-Co-enzyme-A-reductase inhibitor treatment. Atherosclerosis 143: 459-460
13. Bruckert E, Giral P, Heshmati HM, Turpin G (1996) Men treated with hypolipidaemic drugs complain more frequently of erectile dysfunction. J Clin Pharm Ther 21: 89-94
14. Pedersen TR, Faergeman O (1999) Simvastatin seems unlikely to cause impotence. Br Med J 318: 192
15. Chazerain P, Hayem G, Hamza S, Best C, Ziza JM (2001) Four cases of tendinopathy in patients on statin therapy. Joint Bone Spine 68: 430-434
16. Sinzinger H (2002) Flu-like response on statins. Med Sc Monit 8: 384-388
17. Sinzinger H (2002) Statin-induced myositis migrans. Wien Klin Wochenschr 114: 943-944